Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch & Lomb CorpBLCO · Entity 3756 | Please see remarks | March 01, 2023 | March 03, 2023 |
| Bausch Health Companies Inc.BHC · Entity 4363 | EVP AND GENERAL COUNSEL | March 10, 2022 | March 11, 2022 |
| CalciMedica, Inc.GRAY · Entity 7804 | Director | March 23, 2023 | March 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch & Lomb Corp
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 146,677 |
Reported balance
After 2023-03-01 transaction · row 1
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 28,344 · Balance 146,677 F1: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation. |
| Non-Qualified Stock Options (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $17.96 | Direct | 90,744 |
Reported balance
After 2023-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-01 · Grant · Acquired 90,744 · Balance 90,744 F2: Reflects the grant of stock options to purchase Common Shares under the Plan. F3: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement. F4: The stock options will expire on the tenth anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation.
F2: Reflects the grant of stock options to purchase Common Shares under the Plan.
F3: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement.
F4: The stock options will expire on the tenth anniversary of the grant date.
Bausch Health Companies Inc.
Report date March 10, 2022 · Filed March 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 162,240 |
Reported balance
After 2022-03-10 transaction · row 1
1 source rowRow 1 · 2022-03-10 · Tax withholding · Disposed 839 · Balance 162,240 F1: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. |
Filing footnotes · ownership attribution and instrument terms
F1: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.
CalciMedica, Inc.
Report date March 23, 2023 · Filed March 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,429 |
Reported balance
After 2023-03-23 transaction · row 1
1 source rowRow 1 · 2023-03-23 · Disposition to issuer · Acquired 1,429 · Balance 1,429 F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christina Ackermann's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-23 · Disposition to issuer · Disposed 1,429 · Balance 0 F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christina Ackermann's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christina Ackermann's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Verona Pharma plc
Report date October 07, 2025 · Filed October 08, 2025
Section 16 reporting ended · disclosed 2025-10-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2025-10-07 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2025-10-07 · Disposition to issuer · Disposed 64,072 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Row 2 · 2025-10-07 · Exercise / conversion · Acquired 72,000 · Balance 72,000 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Row 3 · 2025-10-07 · Disposition to issuer · Disposed 72,000 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-07 · Exercise / conversion · Disposed 72,000 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2034-04-28 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-10-07 · Disposition to issuer · Disposed 200,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2033-08-31 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-10-07 · Disposition to issuer · Disposed 144,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").
F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").
F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.
F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2020 Filed Mar 12, 2020 00:52 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 4,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-010317 · form4.xml · nonDerivative · entry 3 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,025 F3 · shares: Represents matching Restricted Share Units ("MRSUs") granted to the Reporting Person in connection with the open market purchase of Common Shares reported on Table I above, pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant, subject to the Reporting Person's continued service (except in limited circumstances). Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 00:52 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | PurchaseCommon Shares, No Par Value | 4,390 | $18.25 | $80,105.65 |
DisclosureSEC source: 0001127602-20-010317 · form4.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,635 F2 · price: The price reported above is a weighted average price. This transaction was executed in multiple trades at prices ranging from 18.23 to $18.25. Information regarding the number of shares purchased and the purchase price per share will be provided upon request by the Commission staff, the Issuer or a shareholder of the Issuer. Read SEC document |
| March 09, 2020 Filed Mar 12, 2020 00:52 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 3,343 | $20.96 | $70,069.28 |
DisclosureSEC source: 0001127602-20-010317 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,245 F1 · shares: This number represents common shares, no par value, of the Issuer ("Common Shares") withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:52 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 3,779 | $24.44 | $92,358.76 |
DisclosureSEC source: 0001127602-20-009072 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,588 F1 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:19 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 81,873 | $0.00 Strike: $24.77 | $0.00 |
DisclosureSEC source: 0001127602-20-008431 · form4.xml · derivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,873 Underlying: Common Shares, No Par Value · 81,873 shares Expires 2030-02-26 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:19 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 19,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-008431 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,367 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| February 20, 2020 Filed Feb 22, 2020 02:52 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 22,378 | $26.46 | $592,121.88 |
DisclosureSEC source: 0001127602-20-007076 · form4.xml · nonDerivative · entry 3 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,190 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:52 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionRestricted Share Units · Derivative | 7,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007076 · form4.xml · derivative · entry 4 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. F2 · derivative.exercise_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F2 · derivative.expiration_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 4 filed on January 10, 2017 with the maximum potential award amount of 16,384 shares. Any portion of the award not vested on February 19, 2020 was terminated as of that date. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:52 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Stock, No Par Value | 42,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-007076 · form4.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,568 Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:52 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Stock, No Par Value | 7,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007076 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 6, 2017. F2 · shares: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document |
| February 19, 2020 Filed Feb 29, 2020 00:16 UTC Amendment | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionRestricted Share Units · Derivative | 7,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008429 · form4a.xml · derivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F4 · price: Each PSU converts into Common Shares on a one-for-one basis. F2 · derivative.exercise_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F2 · derivative.expiration_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 4 filed on January 10, 2017 with the maximum potential award amount of 16,384 shares. Any portion of the award not vested on February 19, 2020 was terminated as of that date. Read SEC document |
| February 19, 2020 Filed Feb 29, 2020 00:16 UTC Amendment | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Shares, No Par Value | 7,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008429 · form4a.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 6, 2017. F2 · shares: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F3 · shares: This Form 4/A is being filed solely to reflect the acquisition of 7,864 Common Shares instead of the disposition of Common Shares originally reported on the Form 4 filed on February 21, 2020. F4 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 21:17 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 3,360 | $29.42 | $98,851.20 |
DisclosureSEC source: 0001127602-20-001361 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,165 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 20:03 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Stock, No Par Value | 3,418 | $22.45 | $76,725.56 |
DisclosureSEC source: 0001127602-19-026527 · form4.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,525 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price in Column 4 reflects the average weighted sale price for the transactions aggregated on this Form 4. The sales price per share reported on this Form 4 range from $22.30 to $22.61. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 20:03 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 7,779 | $22.39 | $174,171.81 |
DisclosureSEC source: 0001127602-19-026527 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,943 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:30 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Stock, No Par Value | 3,968 | $24.81 | $98,446.08 |
DisclosureSEC source: 0001127602-19-024534 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,722 F1 · kind: The sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 20:17 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 3,630 | $23.56 | $85,522.80 |
DisclosureSEC source: 0001127602-19-011019 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,690 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:57 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 62,004 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001127602-19-009227 · form4.xml · derivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,004 Underlying: Common Shares, No Par Value · 62,004 shares Expires 2029-02-27 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:57 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Stock, No Par Value | 21,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009227 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,320 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:02 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 3,446 | $21.25 | $73,227.50 |
DisclosureSEC source: 0001127602-19-001759 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,010 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 20:15 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Stock, No Par Value | 4,542 | $25.50 | $115,821.00 |
DisclosureSEC source: 0001127602-18-030504 · form4.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,456 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:15 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Stock, No Par Value | 15,404 | $24.83 | $382,481.32 |
DisclosureSEC source: 0001127602-18-030504 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,998 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 21:04 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 7,779 | $23.52 | $182,962.08 |
DisclosureSEC source: 0001127602-18-025213 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,402 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 01:54 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantRestricted Share Units · Derivative | 13,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011037 · form4.xml · derivative · entry 3 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,638 Underlying: Common Stock · 13,638 shares Expires 2021-03-07 F3 · derivative.exercise_price: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 6,819 and the maximum number that can be distributed is 13,638. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. F3 · derivative.exercise_date: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 6,819 and the maximum number that can be distributed is 13,638. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 01:54 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 60,853 | $0.00 Strike: $15.32 | $0.00 |
DisclosureSEC source: 0001127602-18-011037 · form4.xml · derivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,853 Underlying: Common Shares, No Par Value · 60,853 shares Expires 2028-03-07 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 01:54 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 20,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011037 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,181 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 20:25 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 3,649 | $23.85 | $87,028.65 |
DisclosureSEC source: 0001127602-18-001433 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,724 Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 20:41 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 6,046 | $15.37 | $92,927.02 |
DisclosureSEC source: 0001127602-17-025507 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,373 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 22:32 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantNon-Qualified Stock Options (right to purchase) · Derivative | 60,345 | $0.00 Strike: $14.38 | $0.00 |
DisclosureSEC source: 0001681871-17-000006 · primary_doc.xml · derivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,345 Underlying: Common Shares, no par value · 60,345 shares Expires 2027-03-01 F1 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| January 06, 2017 Filed Jan 11, 2017 00:01 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantRestricted Share Units · Derivative | 16,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001681871-17-000004 · primary_doc.xml · derivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,384 Underlying: Common Stock · 16,384 shares Expires 2020-01-06 F3 · derivative.exercise_price: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 8,192 and the maximum number that can be distributed is 16,384. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured on January 6, 2020 (the "Measurement Date"). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. F3 · derivative.exercise_date: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 8,192 and the maximum number that can be distributed is 16,384. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured on January 6, 2020 (the "Measurement Date"). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. Read SEC document |
| January 06, 2017 Filed Jan 11, 2017 00:01 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 24,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001681871-17-000004 · primary_doc.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,419 F1 · shares: Represents the award of Restricted Share Units ("RSUs") which will vest one-third on each of the three anniversaries following the date of grant, subject to the reporting person's continued service subject to continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). F2 · balance_after: The total number of shares excludes the 78,918 performance-vesting RSUs previously included in Column 5 of the reporting person's Form 4 filed on August 10, 2016, the target number of which granted to the reporting person was 26,306 and the maximum number of which that can be distributed is 78,918. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.